Alkabbani W, Pelletier R, Gamble JM. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors and The Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. Am J Epidemiol 2021 Mar 6. pii: 6159693. doi: 10.1093.
PMID: 33751032